Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate
Vaccine, Volume 27, No. 49, Year 2009
Notification
URL copied to clipboard!
Description
Malaria is a major public health problem in Sub-Saharan Africa. In highly endemic regions infants, children and pregnant women are mostly affected. An effective malaria vaccine would complement existing malaria control strategies because it can be integrated in existing immunization programs easily. Here we present the results of the first phase Ia clinical trial of GMZ2 adjuvanted in aluminium hydroxide. GMZ2 is a malaria vaccine candidate, designed upon the rationale to induce immune responses against asexual blood stages of Plasmodium falciparum similar to those encountered in semi-immune individuals. Ten, 30 and 100 μg of GMZ2 were well tolerated in 30 healthy malaria-naïve German volunteers when given three times in monthly intervals. Antigen-specific antibodies as well as memory B-cells were induced and detectable throughout the one year follow-up of the study. We conclude that GMZ2 is a safe and immunogenic malaria vaccine candidate suitable for further clinical development. © 2009 Elsevier Ltd. All rights reserved.
Authors & Co-Authors
Esen, Meral
Germany, Tubingen
Eberhard Karls Universität Tübingen
Kremsner, Peter G.
Germany, Tubingen
Eberhard Karls Universität Tübingen
Imoukhuede, Egeruan Babatunde
Denmark, Copenhagen
Statens Serum Institut
Imbault, Nathalie
Denmark, Copenhagen
Statens Serum Institut
Leroy, Odile Y.
Denmark, Copenhagen
Statens Serum Institut
Jepsen, Sören B.
Denmark, Copenhagen
Statens Serum Institut
Knobloch, Juergen
Germany, Tubingen
Eberhard Karls Universität Tübingen
Theisen, Michael
Denmark, Copenhagen
Statens Serum Institut
Mordmüller, Benjamin G.
Germany, Tubingen
Eberhard Karls Universität Tübingen
Statistics
Citations: 88
Authors: 9
Affiliations: 2
Identifiers
Doi:
10.1016/j.vaccine.2009.09.011
ISSN:
0264410X
Research Areas
Infectious Diseases
Maternal And Child Health
Study Design
Cohort Study
Participants Gender
Female